Suppr超能文献

既往有缺血性卒中患者的大血管闭塞:不同病因二级预防用药依从性分析

Large-vessel-occlusion in patients with previous ischemic stroke: an analysis of adherence to secondary preventive medication for different etiologies.

作者信息

Kohlhase Konstantin, Schäfer Jan Hendrik, Tako Lisa Marie, Willems Laurent M, Hattingen Elke, Bohmann Ferdinand O, Grefkes Christian, Rosenow Felix, Strzelczyk Adam

机构信息

Department of Neurology and Epilepsy Center Frankfurt Rhine-Main, University Hospital and Goethe University Frankfurt, Frankfurt am Main, Germany.

LOEWE Center for Personalized and Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany.

出版信息

Neurol Res Pract. 2023 May 25;5(1):22. doi: 10.1186/s42466-023-00247-7.

Abstract

BACKGROUND

Large vessel occlusion (LVO) is a severe condition that carries a high risk of morbidity and mortality, underscoring the importance of effective prevention strategies. This retrospective study aimed to analyze the intake of preventive medication at the time of hospitalization in a cohort of recurrent stroke patients presenting with acute LVO.

METHODS

The study assessed the intake of either platelet aggregation inhibitors (PAI), oral anticoagulants (OAC) or statins at admission in patients with recurrent stroke and correlated it with the final classification of LVO. The frequency of those secondary preventive medication in recurrent stroke patients was defined as primary endpoint. The Modified Rankin Scale (mRS) at discharge was used as a functional outcome and defined as a secondary outcome measure.

RESULTS

This study included 866 patients who were treated for LVO between 2016 and 2020, of whom 160 (18.5%) had a recurrent ischemic stroke. OAC (25.6% vs. 14.1%, p < 0.01), PAI (50.0% vs. 26.0%, p < 0.01), or statin therapy (50.6% vs. 20.8%, p < 0.01) at admission were significantly more frequent in recurrent stroke patients compared to patients with a first-time stroke. Concerning LVO etiology in recurrent stroke patients, OAC at admission was taken in 46.8% of cardioembolic LVO, whereas PAI and statin at admission in macroangiopathic LVO were administered to 40.0%; neither PAI nor OAC was taken in 26.0%, 28.3%, and 31.6% of cardioembolic, macroangiopathic, or cryptogenic strokes, respectively. Regardless of stroke recurrence or etiology, there was an increase in mRS at discharge.

CONCLUSIONS

Despite high-quality healthcare, this study suggested a significant proportion of patients with recurrent stroke who were either non-adherent or insufficiently adherent to secondary preventive medication. Given the disability associated with LVO, improving patients' medication adherence and identifying unknown stroke causes are crucial for effective prevention strategies.

摘要

背景

大血管闭塞(LVO)是一种严重疾病,具有较高的发病和死亡风险,这凸显了有效预防策略的重要性。这项回顾性研究旨在分析一组急性LVO复发性卒中患者住院时预防性药物的使用情况。

方法

该研究评估了复发性卒中患者入院时血小板聚集抑制剂(PAI)、口服抗凝剂(OAC)或他汀类药物的使用情况,并将其与LVO的最终分类相关联。复发性卒中患者中这些二级预防药物的使用频率被定义为主要终点。出院时的改良Rankin量表(mRS)用作功能结局,并定义为次要结局指标。

结果

本研究纳入了2016年至2020年间接受LVO治疗的866例患者,其中160例(18.5%)为复发性缺血性卒中。与首次卒中患者相比,复发性卒中患者入院时使用OAC(25.6%对14.1%,p<0.01)、PAI(50.0%对26.0%,p<0.01)或他汀类药物治疗(50.6%对20.8%,p<0.01)的频率明显更高。关于复发性卒中患者的LVO病因,46.8%的心源性栓塞性LVO患者入院时使用了OAC,而大动脉粥样硬化性LVO患者入院时使用PAI和他汀类药物的比例为40.0%;心源性、大动脉粥样硬化性或隐源性卒中患者分别有26.0%、28.3%和31.6%未使用PAI和OAC。无论卒中复发情况或病因如何,出院时mRS均有所增加。

结论

尽管有高质量的医疗保健,但这项研究表明,相当一部分复发性卒中患者未坚持或未充分坚持二级预防药物治疗。鉴于LVO相关的残疾情况,提高患者的药物依从性并确定未知的卒中病因对于有效的预防策略至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a72/10210396/fc0b960a61f4/42466_2023_247_Figa_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验